SCHEMBL15613506

SCHEMBL15613506

Nc1ncnc2c1c(-c1ccc(Br)cc1)nn2C1CCOCC1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 16/20 0.59
▸ PIK3CA P42336 14/20 0.59
▸ PIK3CB P42338 14/20 0.59
▸ PIK3CG P48736 14/20 0.59
▸ PRKDC P78527 14/20 0.59
▸ EGFR P00533 14/20 0.59
▸ ABL1 P00519 13/20 0.59
▸ HCK P08631 13/20 0.59
▸ SRC P12931 13/20 0.59
▸ KDR P35968 13/20 0.59
▸ MTOR P42345 13/20 0.59
▸ EPHB4 P54760 13/20 0.59
▸ PI4KB Q9UBF8 9/20 0.59
▸ RET P07949 2/20 0.59
▸ LCK P06239 1/20 0.57
▸ LYN P07948 1/20 0.57
▸ BTK Q06187 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24096496 0.91 PIK3CD (0.61) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL15613465 0.89 PIK3CD (0.72) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL1318998 0.84 KDR (0.71) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL1319895 0.84 KDR (0.71) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL1319000 0.84 KDR (0.71) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL5803102 0.84 BTK (0.82) EGFRABL1HCKSRCKDR
SCHEMBL24096737 0.84 PIK3CD (0.55) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL20533429 0.82 EGFR (0.58) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL13020103 0.82 KDR (0.74) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL13020092 0.82 KDR (0.74) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
WO-2013177668-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2013-12-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191473-A1 PROTEIN KINASE INHIBITORS TEC, SRC, LCK PIK3CD 357/4885PIK3CA 414/4885PIK3CB 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback